New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2013
05:55 EDTABT, ABT, BSX, BSX, JNJ, JNJ, MDT, MDT, STJ, STJ, EW, EW, ATRC, ATRC, HT, HTLeerink's medical supplies and devices analyst holds a luncheon
Medical Supplies & Devices Analyst Antalffy holds a luncheon meeting where the focus is on current market paradigms and future growth drivers in interventional cardiology at the Variety Club Research Center at the University of Minnesota, Minneapolis on March 20 at 11 am.
News For ABT;BSX;JNJ;MDT;STJ;EW;ATRC;HT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 1, 2015
16:33 EDTJNJGilead submits NDA to FDA for single tablet regimen for HIV containing R/F/TAF
Gilead Sciences (GILD) announced that it has submitted a New Drug Application, or NDA, to the FDA for an investigational, once-daily single tablet regimen that combines Gilead’s emtricitabine 200 mg and tenofovir alafenamide, or TAF, 25 mg with rilpivirine 25 mg, or R/F/TAF, from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), for the treatment of HIV-1 infection in adult and pediatric patients 12 years of age and older. The data submitted in the NDA support the use of R/F/TAF among patients who are HIV treatment-naïve or who are virologically suppressed and want to replace their current antiretroviral treatment regimen. A Priority Review voucher acquired from Knight Therapeutics in November 2014 was submitted to the FDA along with the R/F/TAF NDA. Under the Prescription Drug User Fee Act, or PDUFA, the anticipated target action date for the R/F/TAF NDA is six months after the FDA’s acceptance of the filing. TAF is a novel, investigational nucleotide reverse transcriptase inhibitor, or NRTI, that has demonstrated high antiviral efficacy at a dose less than one-tenth that of Gilead’s Viread, as well as improved renal and bone laboratory parameters as compared to TDF in clinical trials in combination with other antiretroviral agents. In addition to R/F/TAF, two other TAF-based HIV treatments are also under FDA review.
June 30, 2015
08:33 EDTSTJSt. Jude Medical announces launch of ILUMIEN III clinical trial
Subscribe for More Information
June 29, 2015
18:13 EDTMDTMedtronic says AHA/ASA recommends stent retriever technology
Subscribe for More Information
June 25, 2015
12:52 EDTABTEU to decide by July 29 on Mylan's bid for Perrigo, Reuters reports
Subscribe for More Information
11:03 EDTMDTMedtronic announces U.S. launch of Advisa SR MRI SureScan pacing system
Medtronic announced the U.S. FDA approval and commercial launch of the Advisa SR MRI SureScan single-chamber pacemaker with the 5076 MRI lead, which allows for magnetic resonance imaging scans positioned on any region of the body without restrictions. The new system includes the Advisa SR MRI pacemaker and a SureScan lead, which must be used together to be considered MR- conditional.
09:23 EDTMDTMedtronic announces resignation of Christopher O'Connell
Medtronic (MDT) announced in a regulatory filing that Christopher J. O’Connell is resigning as the company’s EVP and President, Restorative Therapies Group. The company also announced the appointment of Geoff Martha as the company’s EVP and President, Restorative Therapies Group, effective immediately. The Fly notes that Waters (WAT) this morning named O'Connell as its new president, CEO and member of its Board of Directors, effective in September.
09:15 EDTMDTWaters names Christopher O'Connell as CEO, effective in September
Subscribe for More Information
June 23, 2015
17:03 EDTMDTMedtronic implements voluntary recall for certain lots of Covidien Shiley tubes
Medtronic announced that on May 8, it began notifying hospitals and distributors worldwide that affected lots of its Covidien Shiley tracheostomy tubes were formed with a wider-angle bend than standard models manufactured after November 29, 2012. The company initiated the field action following a small number of customer complaints that included reports of 12 serious patient injuries, such as breathing difficulties that impacted oxygen levels immediately upon tube placement or discomfort. Replacement of the tracheostomy tube with product manufactured prior to November 29, 2012 addressed the patient breathing difficulty or discomfort. The notification requested all customers and distributors to quarantine and discontinue use of all potentially affected units and return the affected product to the company as soon as possible for credit. Medtronic also took the necessary steps to prevent future shipments of the recalled products. The company also notified regulatory agencies around the world, as appropriate. Since November 29, 2012, Shiley tracheostomy tubes were shipped into Australia, Belgium, Canada, Chile, Germany, Israel, Italy, Japan, Saudi Arabia, Singapore, South Africa, Turkey, Uruguay and the United States of America.
12:35 EDTBSXBoston Scientific CEO says M&A an important strategy
Boston Scientific CEO is speaking in a CNBC interview.
11:20 EDTEW, MDTMedtronic competitive with Edwards after approval, says Wells Fargo
Subscribe for More Information
09:22 EDTMDTMedtronic announces FDA approval for new TAVR system
Subscribe for More Information
08:02 EDTHTHersha Hospitality 1-for-4 reverse share split effective June 22
Hersha Hospitality Trust announced that the previously announced 1-for-4 reverse split of the company’s issued and outstanding Common Shares took effect at 5:00 p.m., EDT, on June 22. Accordingly, at the Effective Time, every four issued and outstanding Common Shares were combined into one Common Share. In addition, at the market open on June 23, the Common Shares began trading on the New York Stock Exchange on a post-split basis under the existing symbol “HT” and under a new CUSIP number: 427825 500. As a result of the reverse share split, the number of outstanding Common Shares was reduced from approximately 191.1 million to approximately 47.8 million. Thecompany’s previously announced second quarter dividend, to be paid on July 15 to the holders of record of Common Shares on the close of business on June 30 will be adjusted to 28c per Common Share. The amount of any future dividends payable by the company will be determined by and at the sole discretion of the company’s Board of Trustees.
07:25 EDTBSX, EW, MDTPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
07:17 EDTEWFeedback on Edwards Lifesciences Centera 'very positive,' says Wells Fargo
Subscribe for More Information
June 22, 2015
09:04 EDTBSXBoston Scientific initiates study to assess EMBLEM S-ICD
Subscribe for More Information
June 21, 2015
12:42 EDTMDTMedtronic reports five-year follow-up results for Endurant AAA stent graft
Subscribe for More Information
June 19, 2015
17:02 EDTMDTMedtronic acquires Aptus Endosystems for $110M
Medtronic announced it has acquired the assets of Aptus Endosystems, a Sunnyvale, Calif. based, privately held medical device company focused on developing advanced technology for endovascular aneurysm repair and thoracic endovascular aneurysm repair. Medtronic completed its acquisition of the assets of Aptus Endosystems in a transaction valued at approximately $110M. Additional terms of the acquisition were not disclosed.
09:23 EDTMDTMedtronic acquires CardioInsight Technologies
Subscribe for More Information
09:21 EDTMDTMedtronic approves repurchase of addition 80M shares
Subscribe for More Information
09:20 EDTMDTMedtronic raises quarterly dividend by 25% to 38c per share
The board of Medtronic approved a 25% increase in its cash dividend for FY16, raising the quarterly amount to 38c per ordinary share for an annual amount of $1.52 per ordinary share. The dividend is payable on July 17, to shareholders of record at the close of business on June 29.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use